Regulation of the PMP22 gene through an intronic enhancer by Jones, Erin A et al.




Regulation of the PMP22 gene through an intronic
enhancer
Erin A. Jones
University of Wisconsin - Madison
Camila Lopez-Anido
University of Wisconsin - Madison
Rajini Srinivasan
University of Wisconsin - Madison
Courtney Krueger
University of Wisconsin - Madison
Li-Wei Chang
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Jones, Erin A.; Lopez-Anido, Camila; Srinivasan, Rajini; Krueger, Courtney; Chang, Li-Wei; Nagarajan, Rakesh; and Svaren, John,
,"Regulation of the PMP22 gene through an intronic enhancer." The Journal of Neuroscience.31,11. 4242-4250. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/221
Authors
Erin A. Jones, Camila Lopez-Anido, Rajini Srinivasan, Courtney Krueger, Li-Wei Chang, Rakesh Nagarajan,
and John Svaren
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/221
Cellular/Molecular
Regulation of the PMP22 Gene through an Intronic Enhancer
Erin A. Jones,1 Camila Lopez-Anido,3 Rajini Srinivasan,3 Courtney Krueger,3 Li-Wei Chang,4 Rakesh Nagarajan,4
and John Svaren2,3
1Program in Cellular and Molecular Biology, 2Department of Comparative Biosciences, and 3Waisman Center, University of Wisconsin, Madison,
Wisconsin 53705, and 4Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri 63110
Successful myelination of the peripheral nervous system depends upon induction of major protein components of myelin, such as
peripheral myelin protein 22 (PMP22). Myelin stability is also sensitive to levels of PMP22, as a 1.4 Mb duplication on human
chromosome 17, resulting in three copies of PMP22, is the most common cause of the peripheral neuropathy Charcot-Marie-Tooth
disease. The transcription factor Egr2/Krox20 is required for induction of high level expression of Pmp22 in Schwann cells but its
activation elements have not yet been determined. Using chromatin immunoprecipitation analysis of the rat Pmp22 locus, we
found a major peak of Egr2 binding within the large intron of the Pmp22 gene. Analysis of a 250 bp region within the largest intron
showed that it is strongly activated by Egr2 expression in reporter assays. Moreover, this region contains conserved binding sites
not only for Egr2 but also for Sox10, which is also required for Schwann cell development. Our analysis shows that Sox10 is required
for optimal activity of the intronic site as well as PMP22 expression. Finally, mouse transgenic analysis revealed tissue-specific
expression of this intronic sequence in peripheral nerve. Overall, these data show that Egr2 and Sox10 activity are directly involved
in mediating the developmental induction of Pmp22 expression.
Introduction
In the peripheral nervous system, the lipid-rich myelin sheath
formed by Schwann cells plays a vital role in axonal function and
stability. The myelin sheath is composed of many structural pro-
teins required for the compact structure of myelin and the genes
encoding such proteins are highly regulated during development.
Genetic defects in the function or level of myelin genes can be
detrimental and lead to peripheral neuropathy. Charcot-
Marie-Tooth disease (CMT) is the most common inherited
peripheral neuropathy, affecting1 in 2500 people. The most
common cause of CMT is a 1.4 Mb duplication of human
chromosome 17, containing the peripheral myelin protein 22
(PMP22) gene (classified as CMT type 1A), and a deletion of
the same region leads to another type of peripheral neuropa-
thy: hereditary neuropathy with liability to pressure palsies
(Lupski et al., 1991; Chance et al., 1993; Suter and Scherer,
2003). Pmp22 is a tetraspan protein required for stable myeli-
nation (Adlkofer et al., 1995) and a number of rodent models
for CMT1A have shown that transgenic overexpression of
Pmp22 causes peripheral neuropathy (Huxley et al., 1996;
Magyar et al., 1996; Sereda et al., 1996; Huxley et al., 1998;
Robertson et al., 2002). Importantly, lowering expression of
Pmp22 improves myelination in rodent models of CMT1A
(Perea et al., 2001; Sereda et al., 2003; Passage et al., 2004).
Pmp22 is highly upregulated along with other myelin genes
in Schwann cells during myelination as well as during remy-
elination following nerve crush injury (Snipes et al., 1992;
Notterpek et al., 1999). Two transgenic studies identified
overlapping upstream segments that lead to Schwann cell-
specific expression (Maier et al., 2003; Orfali et al., 2005). This
upstream region was shown to recapitulate the later expres-
sion of endogenous Pmp22 and has been named the late my-
elination Schwann cell-specific element (LMSE) (Maier et al.,
2003). The region(s) responsible for early developmental ex-
pression have yet to be identified.
Early growth response 2 (Egr2/Krox20, hereafter referred to as
Egr2) is a key regulator ofmyelin genes during early development
(Topilko et al., 1994; Le et al., 2005b; Decker et al., 2006) and is
also required for induction ofPmp22 (Nagarajan et al., 2001; Le et
al., 2005a). Sox10 is required at several stages of Schwann cell
development (Kuhlbrodt et al., 1998; Britsch et al., 2001;
Schreiner et al., 2007; Finzsch et al., 2010) but has not been shown
to directly regulate Pmp22. Interestingly, Sox10 binds near Egr2
at several loci in myelin genes (Jang et al., 2010) and has been
shown to function synergistically with Egr2 at themyelin protein
zero (Mpz) locus (Bondurand et al., 2001; Denarier et al., 2005;
LeBlanc et al., 2006; Jang and Svaren, 2009). Because of their
fundamental role in Schwann cell biology (Svaren and Meijer,
2008), we hypothesize that identifying the Egr2/Sox10 regulated
sites will reveal critical regulatory elements within PMP22. Here
we use chromatin immunoprecipitation (ChIP) of Egr2 and
Sox10 to identify a novel enhancer that drives Schwann cell-
specific expression of Pmp22.
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Materials andMethods
Chromatin immunoprecipitation. ChIP assays on pooled male and
female rat sciatic nerve at postnatal day (P)15 and the S16 cell line
were performed as previously described (Jang et al., 2006; Jang and
Svaren, 2009), except that the S16 cell line was cross-linked in PBS
containing 1% formaldehyde. In addition, the herring sperm DNA in
the blocking procedure was omitted in the in vivo ChIP assays. The
antibodies used in this study include Egr2 (Covance PRB-236P),
Sox10 (Santa Cruz Biotechnology sc-17342X), and control IgG (nor-
mal rabbit IgG, Millipore 12-370; normal goat IgG, Santa Cruz Bio-
technology sc-2028). Following ChIP, quantitative PCR was
performed in duplicate to calculate the fold recovery of a given seg-
ment relative to the nonspecific control, using the comparative Ct
method (Livak and Schmittgen, 2001). All the primers used in this
study are listed in Table 1. All experiments on rats/mice were per-
formed in strict accordance with experimental protocols approved by
the Institutional Animal Care and Use Committee, University of Wis-
consin, School of Veterinary Medicine.
ChIP analysis using tiled microarrays. To combine ChIP with microar-
ray analysis, amplicons were first generated from ChIP products by
whole genome amplification (Sigma). Labeling of the samples with Cy5
(Egr2; Covance) orCy3 (IgG), followed bymicroarray hybridization,was
performed as described previously (Jang and Svaren, 2009; Jang et al.,
2010) by Nimblegen, using a custom microarray designed with isother-
mic probes staggered by 17 bp over the Pmp22 locus. Coordinates of tiled
regions are derived from the Rn4 genome build. Gaps in the tiling rep-
resent repetitive DNA regions for which unique probes could not be
designed. The enrichment ratio of Cy5 to Cy3 was plotted on a log2 scale,
further processed by baselining all peaks to 1% of the highest peak in the
window, and displayed a moving average using a window size of five
probes. Peak finding was performed using the NimbleScan (Nimblegen)
software, with a false discovery rate of 0.05.
Formaldehyde-assisted isolation of regulatory elements.The formaldehyde-
assisted isolation of regulatory elements (FAIRE) assay on the S16 rat
Schwann cell line was performed by first rinsing confluent cells with
PBS and then cross-linking in PBS containing 1% formaldehyde for 5
min at room temperature (22°C). Glycine was added to 125 mM and
incubated for 5 min at room temperature. After washing twice with
cold PBS, the cells were harvested, pelleted, and frozen at80°C. The
cell pellet was thawed and sonicated on ice using the Bioruptor (Di-
agenode) set on high (30 s on, 30 s off; for 20 min) in lysis buffer (150
mMNaCl, 10% glycerol, 50 mM Tris pH 8.0, 2% Triton, 1% SDS, 1 mM
EDTA) containing protease inhibitor mixture (5 l of mixture per
milliliter of buffer) (Sigma). The lysate was cleared by centrifugation
and unbound DNA was extracted with phenol:chloroform and etha-
nol precipitated, as previously described (Giresi and Lieb, 2009). The
protocol only differed in that NaCl was used in the ethanol precipi-
tation. Twenty percent of the cross-linked chromatin was used as an
input control by reversing the cross-links at 65°C overnight before
phenol:chloroform extraction. The samples were analyzed using
quantitative PCR with the same primer sets used in ChIP (Table 1),
performed in duplicate to calculate the relative expression, of a given
segment relative to the input control, using the comparative Ct
method (Livak and Schmittgen, 2001).
Transfection assays. The B16 (mouse melanoma) cell line was grown
and transfected as described previously (Jones et al., 2007; LeBlanc et al.,
2007). The reporter constructs contain the following coordinates from
human chromosome 17 (hg18Mar. 2006 build in UCSC Genome
Browser), cloned upstream of the pGL4 luciferase reporter containing
the minimal E1B TATA promoter except the PMP22 2 kb construct
that contains the native PMP22 P2 promoter; PMP22 7 kb:
15,113,094–15,114,102; PMP222 kb: 15,106,498–15,106,933; PMP22
5 kb: 15,098,299–15,098,685; PMP22 8.5 kb: 15,094,466–
15,094,975; PMP22 11 kb: 15,091,959–15,092,201; PMP22 16 kb:
15,086,052–15,086,906; PMP22 24 kb: 15,075,138–15,075,801. The
mutations of the PMP2211 kb reporter were made using site-directed
mutagenesis. The individual Sox10 sites were changed to G at positions 4
and 5 on the CA-rich strand, which has been previously reported to
abrogate Sox10 binding to DNA (Bondurand et al., 2001). The Egr2 sites
were mutated to A at position 6 of the G-rich strand, which has previ-
ously been shown to abolish binding (Choo et al., 1997).
siRNA treatment and Western blot analysis. Either siRNA directed to-
ward Sox10 (4390771; Ambion) or a negative siRNA control (Negative
control #2, AM4613; Ambion) were transiently transfected into S16 cells
with the Amaxa system (Lonza) using the rat neuron nucleofection so-
lution. The transfected cells were incubated for 48 h before harvesting
RNA using Tri Reagent (Ambion), and quantitative PCR was performed
in duplicate to calculate the relative expression, using the comparative Ct
method (Livak and Schmittgen, 2001).
Lysates from siRNA-treated S16 cells were analyzed by immunoblot-
ting for Sox10 and Pmp22 using a 1:1000 dilution of Sox10 (Santa Cruz
Biotechnology) and a 1:1000 dilution of Pmp22 (Abcam). The mem-
branes were probed with horseradish peroxidase-conjugated anti-rabbit
secondary antibody (Jackson Laboratories) at a dilution of 1:10,000. Lu-
minescence was detected with ECL Plus (Invitrogen) using the Alpha
Innotech Fluorochem HDII imaging system.
Bioinformatic analysis. Regions conserved between humans, rats, and
mice in a 40 kb window surrounding the Pmp22 locus were searched for
Egr2/Sox10 binding sites using a conserved composite element module
previously described (Jones et al., 2007).
Transgenic mice. The transgene used in this study contains the
following coordinates from the human genome (Mar. 2006 build in
UCSC Genome Browser), cloned upstream of the pGL4 luciferase
reporter containing the mouse Hsp68 promoter: chr17: 15,090,965–
15,092,611. The transgene was linearized by restriction digestion
(KpnI and SalI) and microinjected into the pronucleus of FVB/N
one-cell embryos by the University of Wisconsin Waisman Center
Rodent Models Core. Relative copy number of each founder was
determined by using quantitative PCR to normalize the transgene to
an endogenous gene,Hmgcr. At P4, P12, and P30, various tissues were
collected from both male and female mice for luciferase expression
analysis by quantitative reverse transcription PCR.
Immunohistochemistry. Frozen sections of mouse sciatic nerve (6 m)
were fixed in 4% paraformaldehyde in PBS for 15 min at room temper-
ature. After the sections were rinsed with PBS, they were incubated with
permeabilizing solution (0.06% Triton X-100 in PBS) for 20 min. They
were rinsed three times with PBS and incubated in blocking solution (5%
goat serum, 1% BSA in PBS) for 1 h. Sections were incubated with anti-
firefly luciferase (Luc-17) mouse monoclonal antibody (1:100; Abcam)
for 1 h. They were rinsed three times with PBS and incubated with Alexa-
488 secondary antibodies for 1 h. After the sections were rinsed oncewith
PBS, they were incubated with Hoescht 33258 (1:1000; Fisher Scientific)
in PBS for 1 min and then rinsed five times with PBS. The sections were
mounted on slides using Fluoromount-G mounting medium (Southern
Biotech). Immunofluorescent images were visualized via a Nikon C1
confocal microscope.
Results
Identification of Egr2 binding sites in Pmp22
PMP22 is expressed from two different promoters, P1 and P2,
transcribing exon 1A and exon 1B, respectively, which result in
Table 1. Primer sets used in quantitative PCR
Name Forward primer Reverse primer
7 kb TCTGAGCTTTCTCTCTCCCACAG TCCCAGGATGAAGTGCATCTT
2 kb AGGCCCGCCCTCCTGCACACG TTTGCGTCGCTGCAGAAG
5 kb TTCCTCAGGTGTAGCAAAGTCTTG AAGGCCCCCACATGGATA
6.5 kb CCTGGTGTTTTGATTTCCATTTTT CAGGCCAGGTGAAATCAAGAC
8.5 kb CCCAGGCCACCTTCTCAGA ACCAATGCCCTACAGTTCTAATGTT
11 kb CACTGGCCTCTGGGCAAGT GAAACAATGTGGCCTTTGCTC
16 kb TATTTTTGCTTTCTGGAGATGTTCCT GGAGAGGCTTCCAAACTATGTATTG
24 kb TCCCCCTCTATCGCAAACC TGAGTGTAAGTGAGCAGTACCTATTGG
Luciferase GGCTACTTGATCTGCGGCTTT TCCTCCTCGAAGCGGTACAT
End Pmp22 GAGGAAGGGGTTACACCATTG GCAACACTAGCACCGCGAT
End Mpz CCCTGGCCATTGTGGTTTAC CCATTCACTGGACCAGAAGGAG
Hmgcr GGATGGTACCGGTGCTCT AGAAACGAACTGTAGCTC
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two mRNAs that differ only in their 5
noncoding region (Bosse et al., 1994;
Suter et al., 1994). Both the P1 and P2
promoters are upregulated during myeli-
nation, but expression from P1 is
Schwann cell-specific, whereas P2 is ex-
pressed in other tissues, such as brain,
heart, lung, and gut. As myelination pro-
gresses, the transcript originating from P1
becomes the predominant form in rodent
peripheral nerve, whereas the ratio of P1
to P2 in human peripheral nerve is ap-
proximately equal (Suter et al., 1994).
Transfection studies of Pmp22 expression
have shown that the P1 promoter can
drive expression of a reporter in Schwann
cells (Suter et al., 1994; Sabe´ran-Djoneidi
et al., 2000; Hai et al., 2001). However,
additional regulatory elements are in-
volved since the P1 promoter is unable to
independently drive consistent expres-
sion in peripheral nerve of transgenic
mice (Maier et al., 2003).
Since Egr2 activates Pmp22 expression
(Nagarajan et al., 2001; Le et al., 2005a),
we sought to identify Egr2 binding sites as
a means to discover critical Pmp22 en-
hancer elements. We therefore adapted
Egr2 ChIP assays in the S16 rat Schwann
cell line for analysis with a tiled microar-
ray (ChIP–chip) containing 200 kb sur-
rounding the rat Pmp22 gene (Fig. 1A).
The S16 cell line expresses high levels of
myelin genes, includingPmp22, compara-
ble to those in myelinating Schwann cells
(Hai et al., 2002). Egr2 ChIP DNA was
cohybridized to the custom array along
with control IgG ChIP DNA, and the fluorescence ratio was plot-
ted relative to the position within the Pmp22 locus. The results
show amajor peak at11 kb (relative to the translation start site)
within the largest intron of the Pmp22 gene, along with some
more minor peaks distributed throughout the gene.
Several sites with various levels of Egr2 binding were chosen
for further analysis (Fig. 1A, arrows). The site at7 kb is within
a larger region previously shown to drive Schwann cell-specific
expression inmice (Maier et al., 2003; Orfali et al., 2005). The2
kb region is just upstream of the P2 promoter, expressing exon
1b. Several intronic sites in uncharacterized regions of Pmp22
were also chosen for further analysis, including the major peak at
11 kb. Egr2 binding at these sites was validated by quantitative
PCR analysis of independent ChIP samples from the S16 cell line,
revealing high levels of Egr2 at 11 kb relative to a control im-
munoprecipitation (Fig. 1B). Moreover, we also performed in
vivo ChIP assays using P15 rat sciatic nerve, which is an optimal
time point for detection of Egr2 binding by ChIP (Jang et al.,
2006;Mager et al., 2008; Jang and Svaren, 2009). The in vivoChIP
assay demonstrated a significant level of binding at 11 kb,
consistent with the ChIP assays in the S16 cell line (Fig. 1C).
Many of the minor peaks in the ChIP– chip analysis do not
exhibit significant Egr2 binding above background in quanti-
tative PCR analysis of ChIP samples from S16 cells or in vivo.
The 11 kb region appears to be the predominant region for
Egr2 binding during myelination.
Activation of PMP22-derived segments in reporter assays
To determine whether Egr2-bound regions have enhancer activ-
ity, many of the regions chosen for further analysis in the ChIP
assay were tested for their response to Egr2 expression in a lu-
ciferase reporter assay. Segments were cloned upstream of amin-
imal TATA promoter driving luciferase except 2 kb, which
contains the P2 promoter (Fig. 2A, arrows). As many of these
segments contained conserved sequences, the homologous hu-
man sequences were used to create the reporter vectors.
The reporters were tested in the B16/F10 melanoma cell line,
which expresses Sox10 (Kamaraju et al., 2002) but not Egr2
(Slutsky et al., 2003), for activation by cotransfection of an Egr2
expression construct. The 11 kb reporter from the largest in-
tron was highly activated in response to Egr2, whereas the other
six reporters were not strongly activated. The11 kb region also
showed the strongest Egr2 binding in the ChIP assays (Fig. 1),
indicating that Egr2 binding is correlated with enhancer activity
in this assay.
Identification of functional Sox10 and Egr2 sites in the
11 kb enhancer
Analysis of the human 11 kb element revealed four putative
Egr2 sites and one putative dimeric Sox10 site, which are variably
conserved the in rat, mouse, and human genomes (Fig. 2B). The
11 kb reporter construct used above was mutated to test the
importance of these sites in Egr2 activation. The Egr2 sites were
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Figure1. ChIP– chip analysis of thePmp22 locus.A, ChIP– chip analysis of Egr2bindingwasperformed in S16 rat Schwann cells
with a custom tiled array containing the Pmp22 locus. The enrichment ratio of Cy5-labeled Egr2 ChIP DNA to Cy3-labeled IgG ChIP
DNAwas plotted on a log2 scale and further processed by baselining to 1% of the highest peak and displayed a five-point moving
average. Peak analysiswas performed (NimbleScan)with a false discovery rate of 0.05. A significant peak at11 kbwas observed
in two independent Egr2 ChIP– chip experiments and the peak at6.5 was only detected in one of the two experiments. Below,
Noncoding exons (white boxes), coding exons (gray boxes), alternative transcription start sites (P1 and P2), and regions chosen for
further analysis (downward arrows) with their distance relative to the translation start site are indicated. B, S16 ChIP assays for
Egr2 binding were analyzed by quantitative PCR with indicated primer sets. The graph indicates fold enrichment at each site
relative to an IgG control ChIP assay. Error bars represent the SD of two technical replicates. The fold enrichment of the signal at the
11 kb site was at least ninefold in three independent experiments. C, In vivo ChIP assays for Egr2 bindingwere performed using
pooledP15 rat sciatic nerve andanalyzedbyquantitative PCRusing the sameprimers sets as inB. Error bars represent the SDof two
technical replicates. The fold enrichment of the signal at the11 kb sitewas at least eightfold in three independent experiments.
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mutated to A at position 6 of the G-rich strand, which has previ-
ously been shown to abolish binding (Choo et al., 1997).When all
four sites were mutated, the Egr2 activation was abolished (Fig.
3A). To determine which of the four Egr2 sites are functional, the
Egr2 sites were each mutated individually (Fig. 3B). Transfection
analysis of the resulting promoter constructs showed that mutat-
ing Egr2 site 2 had the largest effect, whereas reporter activity was
relatively unimpaired by mutation of sites 1 or 3. There was an
50% decrease with mutation of site 4.
Subsequently, reporter constructs were created in which all
but one of the putative Egr2 sites were mutated (Fig. 3C). In this
series, the construct containing Egr2 site 2 was most highly acti-
vated, yielding a 179-fold activation, which is approximately one-
fifth of the activity of the wild-type element. Egr2 sites 3 and 4
support a lower level of activation in this assay, suggesting that
they can mediate some of the Egr2 activation. In both sets of
constructs, the Egr2 site 1 does not appear to contribute to re-
porter activity (Fig. 3B,C). Therefore, sites 2–4 appear to be
largely responsible for the strong activation of the 11 kb ele-
ment in transfection assays. Using a recently defined binding site
matrix for Egr1 (Berger et al., 2006), which has an identical DNA
binding domain to Egr2, sites 2 and 3 are most conserved, espe-
cially at the bases that aremost critical for binding. AlthoughEgr2
site 4 in the human sequence would be predicted to be a high
affinity site, it is less well conserved in rat and mouse.
To determine whether the Sox10 site is functional, the ade-
nines at positions 4 and 5 of the CA rich strand (AACAANG)
were mutated to G in both sides of the dimeric Sox10 site, which
has previously been shown to disrupt Sox10 binding (Bondurand
et al., 2001). Mutating the Sox10 sites lowered the Egr2-
dependent activation, suggesting that Egr2 activation requires
Sox10 binding at this site (Fig. 3A). Although theB16/F10 cell line
expresses Sox10, cotransfection of 100 ng of Sox10 expression
plasmid further activated the11 kb reporter 14-fold2.4. The
Sox10 mutation decreased Sox10 activation of the 11 kb re-
porter to 1.8-fold0.3, suggesting that this is a functional Sox10
site and the11 kb element is dependent on both Egr2 and Sox10
for activation.
A
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Figure 2. Reporter analysis of selected human PMP22 segments.A, The indicated segments
of the human PMP22 gene were placed upstream of a luciferase reporter gene containing a
minimal TATAelement, except the2kb reporter,which contains thePMP22P2promoter. The
PMP22 reporters were cotransfected in the B16/F10 cell line with expression plasmids for Egr2
(25 and 50 ng). Fold induction is calculated relative to the activity of each reporter alone and
reported on a log10 scale. Error bars represent SD (n 6). B, The11 kb region of human
PMP22 is diagramed with four putative Egr2 sites (numbered boxes) and one putative dimeric
Sox10 site (ovals). The sequence alignments show conservation of the binding sites in humans
(h), mice (m), and rats (r). The monomeric Sox10 binding sites are underlined and the nucleo-
tides mutated by site-directed mutagenesis are indicated (*).











Figure 3. Functional analysis of Egr2 and Sox10 sites within the11 kb enhancer. A, Mu-
tated sites are indicated by filled symbols, and the various mutant11 kb reporters were
cotransfected in B16/F10 cells with expression plasmids for Egr2 (25 ng). Fold induction is
calculated relative to the luciferase activity of each reporter alone. Error bars represent SD (n
6). B, The four Egr2 sites were mutated by site-directed mutagenesis, indicated by filled sym-
bols. The reporters were cotransfected in B16/F10 cells with expression plasmids for Egr2 (25
ng). Fold induction, means, and SD (n 6) are calculated as in A. C, Reporter constructs were
created in which all but one Egr2 site was mutated, indicated by filled symbols. The reporters
were tested for Egr2 induction as in B (n 6).
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Sox10 regulates Pmp22
Since the dependence of Pmp22 expres-
sion on Sox10 activity has not been tested
previously, we examined Pmp22 levels in
S16 Schwann cells treated with siRNA di-
rected against Sox10 (Fig. 4A). At 48 h
after transfection, quantitative reverse
transcriptase (RT)-PCR analysis revealed
a significant decrease in Sox10mRNA lev-
els, and Western analysis showed a de-
crease in Sox10 protein (Fig. 4A,B). This
reduction was observed for both Pmp22
transcripts using primer sets specific for
exons 1a and 1b. Similar results were ob-
tained using two independent siRNAs di-
rected toward Sox10 (data not shown).
Previous work has shown that Sox10 is
required for expression of Egr2 in myeli-
nating Schwann cells (Ghislain and Char-
nay, 2006; Finzsch et al., 2010; Reiprich et
al., 2010). Consistent with these findings,
Egr2 levels were reduced by Sox10 deple-
tion in the S16 cell line. Since the effect of
Sox10 on Pmp22 expression could beme-
diated indirectly through regulation of
Egr2, ChIP assays were used to detect
Sox10 binding within the Pmp22 locus
(Fig. 4C,D). ChIP assays were performed
using an antibody directed against Sox10
in both the S16 rat Schwann cell line and
in vivo using rat sciatic nerve. The Sox10
ChIP was analyzed using the same primer
sets used to detect Egr2 occupancy and revealed that Sox10 coin-
cides with Egr2 binding at the 11 kb site. However, we also
observed Sox10 binding at other sites across Pmp22, with the
highest amount of Sox10 binding at the 7 kb site that resides
within the previously defined LMSE (Maier et al., 2003).
To test the specificity of the Sox10 ChIP assays, the same assay
was also performed in S16 cells in which Sox10 levels were de-
pleted by Sox10 siRNA (Fig. 4C). For the sites examined, the
percentage recovery was severely reduced, indicating that the
ChIP assays detected specific binding of Sox10 to those sites.
Accordingly, the Sox10 antibody detects a single band in the
Western blot (Fig. 4B).
Egr2 and Sox10 bound regions are in regions of
open chromatin
To further test for common characteristics of enhancer elements,
FAIRE was used in S16 cells to identify areas of open chromatin
(Giresi et al., 2007), which are typically present in regulatory
regions (Felsenfeld andGroudine, 2003). This technique relies on
the fact that enhancers often reside in nucleosome-depleted re-
gions. BecauseDNA ismost efficiently cross-linked to histones by
formaldehyde, phenol extraction of protein-cross-linked DNA
results in preferential enrichment of nucleosome-free regions of
the genome. The FAIRE analysis shows that there is selective
enrichment of DNA surrounding the7 kb,2 kb, and11 kb
regions, consistent with areas of open chromatin (Fig. 5). We
expected the2 kb region to have open chromatin because it is
directly upstream of the active P2 promoter (Hai et al., 2002),
and FAIRE specifically enriches for nucleosome-free regions
at promoters of highly transcribed genes (Hogan et al., 2006).
Similar regions of open chromatin were found in a previous
study from our lab using in vivo FAIRE from P15 rat sciatic
nerve (Jang et al., 2010). The regions of open chromatin at7
kb and11 kb are consistent with the hypothesis that these are
enhancer elements.
Sequence analysis of Egr2 and Sox10 sites in the Pmp22 locus
The Pmp22 locus was also screened for conserved occurrences of
a composite matrix containing consensus sequences for both
Egr2 and dimeric Sox10 sites. Using a compositematrix provided
a more reliable prediction of enhancer elements in myelin genes
than identification of Egr2 or Sox10 sites alone (Jones et al.,
2007). Performing this screen for composite sites conserved in
mouse, rat, and humanPMP22 genes identified three regions that
contain the Sox/Egr2 binding module (Table 2). One region is at
the 11 kb site, a second is at the 7 kb site, and the third is at
45 kb in relation to the translation start site and far downstream
of the 3 end of Pmp22. The 45 kb Egr2 sequence has an A at
position 6 of the G-rich strand, which has previously been shown
to abolish binding (Choo et al., 1997), making this a poor site.
Our data have shown that the intronic enhancer at 11 kb is
regulated by Egr2 and Sox10, again showing that this composite
matrix has predictive value. We did observe high levels of Sox10
binding at the7 kb sites, and there was a small response of this
region to Sox10 in transfection studies (data not shown). How-
ever, reporter studies of this site failed to show any response to
Egr2, and theChIP data showed relatively low binding of Egr2. As
mentioned, the 7 kb region used here represents only a small
portion of a larger region that has been shown previously to drive
Schwann cell-specific expression (Maier et al., 2003; Orfali et al.,
2005), so it is possible that Egr2-responsive elements are located

























































Figure 4. Regulation of Pmp22 by Sox10. A, S16 cells were transfectedwith siRNA targeted to Sox10. Quantitative RT-PCRwas
used to compare themRNA levels of Sox10 and Pmp22 expression, using promoter-specific primers for the P1 and P2 promoters of
the Pmp22 gene. Levels in the Sox10 siRNA-treated cells (siSox10) were normalized to the negative control (siCon). Error bars
represent SD (n 3). B, Protein lysates from S16 cells treated with the indicated siRNAs were blotted with antibodies directed
toward Sox10 and Pmp22 relative to actin or-tubulin as a loading control. The bottom two bands correspond to the previously
described 18 and 22 kd bands (Pareek et al., 1997). C, Sox10 ChIP assays were performed in S16 rat Schwann cells treated with
either control or Sox10 siRNA. Samples were analyzed using quantitative PCR and percentage recovery is calculated relative to
input. Error bars represent the SD of two technical replicates. The signal was diminished in the siSox10 sample by an average of
20-fold at the7kb site andanaverageof 21-fold at the11kb site in three independent experiments.D, In vivo Sox10ChIPwas
performed using pooled sciatic nerve from P15mice alongside an IgG control, using the same primer sets as shown in C. Error bars
represent the SD of two technical replicates. The signal was enriched an average of 12-fold at the7 kb site and an average of
3.5-fold at the11 kb site in three independent experiments.
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The11 kb element drives tissue-specific expression
The LMSE region upstream of Pmp22, comprising 3.5 kb
surrounding the 7 kb element, has been shown to drive
tissue-specific expression of a lacZ reporter in transgenic mice
late in development (Maier et al., 2003). We hypothesized that
the11 kb element could also drive tissue-specific expression
and may account for earlier developmental expression of
Pmp22. Transgenic injections were performed with the region
surrounding the 11 kb element driving a luciferase reporter
with the Hsp68 promoter (Fig. 6A). This promoter has very
low levels of expression in peripheral nerve and it has been
used extensively to test tissue specificity of regulatory elements
in transgenic experiments (Kothary et al., 1988; Rossant et al.,
1991; Mandemakers et al., 2000; Forghani et al., 2001; Maier et
al., 2003; Visel et al., 2009). Seven of 12 positive founders had
luciferase expression in the sciatic nerve but not liver by quan-
titative RT-PCR analysis (Fig. 6B), suggesting that this region
drives tissue-specific expression in Schwann cells. To deter-
mine the developmental regulation of the intronic enhancer,
lines were developed from two of the founders, lines D and E,
and sciatic nerve was sampled at P4 and P12 (Fig. 6C). Both
lines had somewhat higher expression at P12 relative to P4,
which is similar to two other endogenousmyelin genes, Pmp22
and Mpz. P30 mice were also tested for luciferase expression
and the expression differed no more than 2.5-fold compared
with the expression at P12 (data not shown). Expression at P4
suggests that the 11 kb region, at least in part, accounts for
the earlier developmental expression of Pmp22 in myelinating
Schwann cells, since transgenic studies of the upstream LMSE
yielded undetectable levels of the reporters at P4 (Maier et al.,
2003).
In addition to sciatic nerve and liver, we also sampled heart,
lung, kidney, spleen, and brain from lines D and E, and used
quantitative RT-PCR to detect luciferase mRNA in these tissues
(Fig. 6D). Line E had very high expression in the lung, possibly
due to insertion near an active enhancer element in lung. Expres-
sion in the sciatic nerve suggests that this element is important to
Schwann cell expression ofPMP22 and the residual activity of this
11 kb element in other tissues suggests that it may play a role in
the basal level of Pmp22 mRNA expression observed in other
tissues (Suter et al., 1994). Finally, expression of the luciferase
protein was observed by immunohistochemistry in sciatic nerve
of a P50 mouse from line E (Fig. 6E).
Discussion
The activation of PMP22 is regulated spatially and temporally to
achieve the critical levels of PMP22 required for proper myelin
formation. Previous studies have characterized the regions up-
stream of the Pmp22 promoter that are critical to its regulation
(Suter et al., 1994; Sabe´ran-Djoneidi et al., 2000; Hai et al., 2001;
Maier et al., 2002, 2003; Orfali et al., 2005). However, Maier et al.
indicated that other regions of Pmp22 are likely required, partic-
ularly for the early induction of Pmp22 during myelination. Us-
ing ChIP–chip analysis of 200 kb surrounding the Pmp22 gene,
we found a novel11 kb intronic enhancer driven by both Egr2
and Sox10. Because the region upstream of Pmp22 has been
shown to drive Schwann cell-specific expression late in develop-
ment, we speculated that the 11 kb enhancer may account for
the earlier expression of Pmp22, and the transgenic data are con-
sistent with this hypothesis. Since ChIP assays detect higher levels
of Egr2 binding at11 kb, a possible explanation for the earlier
expression of the 11 kb element in transgenic studies is that
Egr2 has a higher affinity for this site. Therefore, Egr2 must ac-
cumulate to higher levels inmyelinating Schwann cells to activate
the upstream enhancer. However, these elements probably do
not act in an isolated manner and it is likely that temporal regu-
lation depends upon looping-mediated interactions between
these two enhancers (and perhaps others) and the promoters that
set the critical level of Pmp22 transcription.
Although the 7 kb region was not activated by Egr2 in
reporter assays, it should be noted that the sequences that we
used represent only a fraction of the previously reported 3.5 kb
LMSE region (Maier et al., 2003), possibly explaining why it
was not activated in our Egr2 activation assays. In the ChIP
assays, we observed a high level of Sox10 binding at 7 kb,
whereas Egr2 binding was higher at 11 kb. In fact, although
the7 kb reporter did not respond to Egr2 in the transfection
assay, it responded slightly to Sox10 (data not shown). This
leads us to speculate that the varying strengths of Egr2 and
Sox10 binding establish temporally regulated binding at each
PMP22 enhancer and leads to more sensitive regulation of
PMP22 during development.
Previous work has shown that Egr2 is required for Pmp22
expression (Nagarajan et al., 2001; Le et al., 2005a), but investi-
gating the role of Sox10 in regulation of PMP22 in myelinating
Schwann cells has been complicated because of the early embry-
onic lethality of Sox10-nullmice (Britsch et al., 2001). Hypomor-
phic alleles and a conditional knock-out of Sox10 have been
generated that permit further differentiation of Schwann cells
(Schreiner et al., 2007; Finzsch et al., 2010), but these fail to
activate Egr2 expression, consistent with previous studies show-
ing that Sox10 binds to themyelinating Schwann cell enhancer of
the Egr2/Krox20 gene (Ghislain and Charnay, 2006; Reiprich et
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Figure 5. Analysis of open chromatin in the Pmp22 locus. A diagram of Pmp22 indicates
regions chosen for FAIRE analysis, in which areas of open chromatin are selectively enriched by
phenol extraction of cross-linked chromatin. The percentage recoverywas calculated relative to
total input. Error bars represent the SD of two technical replicates.















7 kb 6533 9.54 4 6470 5.52 63
11 kb 11567 8.07 4 11492 4.72 75
11553 6 14
11689 6.81 122
45 kb 49424 8.51 4 49446 5.28 22
Sites within a 100 kb window surrounding the mouse Pmp22 locus (chr11:62,909,000–63,009,000, mm9) were
predicted using a conserved composite matrix described previously (Jones et al., 2007). Such sites conserved in
human and rat genomes are shown. The sites are numbered relative to the mouse Pmp22 P1 promoter.
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similarly reduced Egr2 levels, indicating
that Sox10 depletion may indirectly affect
Pmp22 expression through downregula-
tion of Egr2. However, direct regulation
of Pmp22 by Sox10 is supported by the
detection of Sox10 binding in the Pmp22
locus by ChIP assays, and the observed ef-
fects ofmutating the Sox10 site in the11
kb enhancer.
Both ascorbic acid and progesterone
antagonists lower Pmp22 levels and im-
prove the phenotype in mouse and rat
models of CMT1A (Sereda et al., 2003;
Passage et al., 2004). Ascorbic acid affects
Pmp22 through inhibition of the cAMP
pathway (Kaya et al., 2007) and although
it has not been shown directly that Egr2 is
involved, Egr2 is induced through the
cAMP pathway (Zorick et al., 1996). In
the case of progesterone antagonists, it
also has not been shown directly to in-
volve Egr2 and Sox10, but progesterone
induces both Egr2 and Sox10 (Guennoun
et al., 2001; Magnaghi et al., 2007) and
they are presumably downregulated with
progesterone antagonist treatment. Al-
though it has not been shown whether
Egr2 or Sox10mediate the effects of ascor-
bic acid or progesterone antagonists, our
data support a model of Pmp22 regula-
tion, at least in part, through Egr2 and
Sox10.
Other studies describe the interaction
of Egr2 and Sox10 in regulatory elements
in the Connexin 32 and Mbp genes (Bon-
durand et al., 2001; Denarier et al., 2005),
and Egr2 and Sox10 bind cooperatively at
an intronic regulatory element inMpz and
physically interact (LeBlanc et al., 2007). In addition, ChIP–chip
analysis of a larger set of myelin genes revealed that Sox10 colo-
calizes with Egr2 more often than would be expected by chance
(Jang et al., 2010). Reporter analysis of the intronic element in
Pmp22 revealed that Egr2 activation of this element is dependent
upon Sox10. Furthermore, Pmp22 activation is sensitive to a dom-
inant mutant of Egr2 (Nagarajan et al., 2001), which disrupts co-
operative interactions between Egr2 and Sox10 (LeBlanc et al.,
2007), suggesting that Egr2 and Sox10 are working cooperatively
at Pmp22. We previously proposed a composite matrix of Egr2
and Sox10 binding sites as ameans to predict regulatory elements
in myelin genes (Jones et al., 2007). Interestingly, application of
this matrix to the Pmp22 gene identified only three such sites in
which Egr2 and Sox10 binding sites are conserved. One was
within the LMSE segment upstream of the gene, and the other
coincided with the intron regulatory element that we have char-
acterized. Overall, these data are consistent with a model of Egr2
and Sox10 binding inmyelin loci, where both Egr2 and Sox10 are
required for full activation of the loci where they bind.
The upstream and intragenic binding of Egr2 and Sox10 is
similar to the enhancer pattern found in another highly expressed
myelin gene, Mpz (Jang and Svaren, 2009). Finding this pattern
leads us to hypothesize that this is a common mechanism of
transcriptional activation. Perhaps these sites interact, altering
the chromatin architecture and leading to transcriptional activa-
tion through anunknownmechanism. Enhancer interactionmay
be promoted by theDNAbending properties of Sox10 (Werner et
al., 1995; Peirano and Wegner, 2000). Further work will be
needed to determine whether these elements interact in vivo.
Although we have focused on Pmp22 transcriptional regula-
tion, there is a large body of work on Pmp22 posttranscriptional
regulation. Pmp22 protein is highly regulated and is turned over
quickly by the proteasome (Pareek et al., 1997; Notterpek et al.,
1999). A point mutation or extra copies of Pmp22 lead to an
accumulation of the protein that overwhelms the degradation
pathway, leading to the CMT1A phenotype (Fortun et al., 2003,
2006). In addition, recent studies of micro-RNAs have found
that, whereas Pmp22mRNA is expressed in other tissues in addi-
tion to peripheral nerve, protein expression is much more selec-
tive because of the effects ofmicro-RNAs (Lau et al., 2008; Verrier
et al., 2009). The expression of our transgenic construct in tissues
other than sciatic nervemay reflect the lack of knownmicro RNA
binding sites in the Pmp22 3 UTR.
Our finding of a new enhancer in PMP22 has significant ther-
apeutic implications for peripheral neuropathies. It is possible
that noncoding mutations in regulatory elements may be associ-
ated with human peripheral neuropathies. In addition, regula-
tory element polymorphisms may be a factor that contributes to
the range of severity experienced by CMT1A patients. Finally,


















































































Copy number: 15 9 78 6 9 1 7
Figure 6. The11 kb enhancer drives developmentally regulated, tissue-specific expression in transgenicmice.A, A segment
of the human PMP22 gene containing the11 kb enhancer was cloned upstream of a luciferase reporter gene and used for
transgenic injection. B, Relative luciferase expression in sciatic nerve from each transgenic founder was normalized to 18S ribo-
somal RNA expression. Expression is shown relative to the highest expressing founder, whichwas set at 100%. The transgene copy
number of each founder is shown below the x-axis. Copy number was determined by normalizing to the endogenous Hmgcr gene
and is relative to the lowest expressing founder, which was set at 1. C, Relative luciferase, endogenous Pmp22, and endogenous
Mpz expression in sciatic nerve and liver were analyzed from two founders at P4 and P12 normalized to 18S ribosomal RNA
expression. Expression levels are shown relative to levels at P4, which are set as 1.D, Luciferase expressionwas determined in two
independent transgenic lines at P12 from sciatic (sc.) nerve, brain, lung, heart, spleen, liver, and kidney, and normalized to 18S
ribosomal RNA expression. Expression levels are shown relative to levels in sciatic nerve, which was set as 1. E, Sections of
transgenic or wild-type (WT) sciatic nerve were stained using an antibody directed against luciferase. The cell nuclei were stained
using DAPI. This is representative of two independent experiments.
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expected to contribute toward development of novel treatment
strategies for CMT1A by facilitating identification of compounds
that reduce PMP22 expression.
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